Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6375104 | 0.92 | MAP2K4 (0.58) | MAP2K4PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6370068 | 0.92 | MAP2K4 (0.48) | MAP2K4PTGER1MAPTJAK2JAK1 | |
| SCHEMBL6370428 | 0.90 | MAP2K4 (0.47) | MAP2K4PTGER1MAPTJAK2JAK1 | |
| SCHEMBL6375165 | 0.84 | PTGER1 (0.51) | MAP2K4PTGER1SCN9AMAPTJAK2 | |
| SCHEMBL6370071 | 0.84 | MAP2K4 (0.46) | MAP2K4PTGER1DHODHMAPTJAK2 | |
| SCHEMBL6369989 | 0.83 | MAP2K4 (0.43) | MAP2K4PTGER1MAPTJAK2JAK1 | |
| SCHEMBL6369555 | 0.82 | MAPK8 (0.47) | MAP2K4PTGER1MAPTRORC | |
| SCHEMBL6370211 | 0.82 | MAP2K4 (0.44) | MAP2K4PTGER1JAK2JAK1RORC | |
| SCHEMBL1513019 | 0.82 | MAP2K4 (0.63) | MAP2K4PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6370625 | 0.82 | MAPK8 (0.51) | MAP2K4PTGER1MAPTJAK2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | MAP2K4 2785/4885PTGER1 2789/4885DHODH 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.